Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $37 to $39.
Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $37 to $39.